ESCHER-GROUP
9.10.2018 07:12:12 CEST | Business Wire | Press release
Post-Expo 2018, Booth #B1.360 – Escher Group , the company transforming the postal and courier market with their innovative customer engagement platform, today announced that Nick Manolis has been named chief executive officer (CEO) of Escher, and that he has also been appointed to the company’s board of directors. For more than two decades, postal operators and couriers have relied on Escher to improve their customer experience at all points of engagement, accelerate service delivery and help them to transform their business to a more efficient variable cost model in a budget-constrained world. Escher has emerged as the worldwide market leader in customer engagement solutions for postal point-of-service (POS), and Manolis will be responsible for leading the company’s continued global expansion.
“Nick is a proven executive in leading high-performing, customer-centric technology companies,” said Matthew Peacock, founding partner at Hanover and Escher board member. “That talent combined with his success in innovating global retail platform solutions makes him a perfect fit to lead Escher as the company looks to expand its reach globally into new countries, and postal and courier markets.”
Outdated IT infrastructure and antiquated operating models no longer work for postal operators and couriers who need to manage the growth of parcels and adapt to today’s digitally savvy customers who want to be engaged on their own terms. Forward-looking postal executives are investing in customer engagement platforms to provide the best customer experience, increase revenues and move to a variable cost model.
With its unique and purpose-built customer engagement platform, Escher enables postal operators to shift to modern and profitable customer engagement strategies that embrace today’s digitally disruptive world. With new and deeper points of engagement – including third-party locations, kiosks, expanded pick-up drop-off (PUDO) locations and mobile point of sale – Escher makes it easier for postal customers to do business. Escher drives efficiency by automating and streamlining business processes and easily operationalizing new points of engagement. New services can be rolled out in days and third-party services can be implemented overnight.
With 25 unique post-centric technology patents, Escher has been able to deploy more than 350 thousand customer engagement points globally, which has resulted in more than two billion transactions processed annually. Escher has transformed how 35 postal operators around the globe profitably interact with their customers.
“Postal operators and couriers worldwide rely on Escher as they make the shift to a modern and profitable customer engagement strategy and embrace today’s digitally disruptive world. Our platform allows them to rapidly deliver new services and capabilities, while also providing a superior customer experience. With Escher, postal executives can do more with the resources with which they are entrusted,” said Nick Manolis. “I am honored to work with the exceptional team at Escher and the posts we serve globally.”
Manolis has spent the last ten years at TrueCommerce, a global provider of retail trading partner connectivity and integration solutions, as president and CEO. Under Manolis’ leadership, TrueCommerce provided a global trading platform that connected 12,000 suppliers with nearly 92,000 retailers worldwide.
Meet Manolis and the Escher team, and learn more about Escher’s customer engagement platform at Post-Expo booth #B1.360.
About Escher
Escher is transforming postal operators and couriers worldwide, enabling them to engage today’s digitally savvy customers across all points of engagement. With Escher’s unique, purpose-built customer engagement platform, posts can drive superior customer experience, with greater speed and better economics. Learn more: www.eschergroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005847/en/
Contact:
Media Contact 280blue, Inc. Amanda McKinney amanda@280blue.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom